Сравнение методов

	Шкала качества жизни, связанного со здоровьем при ГЭРБ	Диагностические критерии синдрома раздраженного кишечника по Рим IV	Краткий опросник по воспалительным заболеваниям кишечника
Область	Гастроэнтерология	Гастроэнтерология	Гастроэнтерология
Семейство	Process / pipeline	Process / pipeline	Process / pipeline
Год появления	1996	2016	2004
Автор метода	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Rome Foundation (multinational expert consensus)	Guyonnet, D., Chassany, O., Ducroc, R., et al.
Тип	Self-report	Diagnostic Criteria	Self-report
Основополагающий источник	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
Другие названия	GERD-HRQL, GERD-HRQoL	Rome IV IBS, Rome Criteria	IBDQ-32, Short IBDQ
Связанные	4	4	4
Сводка	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.